H.C. Wainwright initiated coverage of Collegium Pharmaceuticals (NASDAQ:COLL) with a “buy” rating and $21 price target. The stock closed at $10.21 on Sept. 8.Read More
H.C. Wainwright initiated coverage of Concert Pharmaceuticals (NASDAQ:CNCE) with a “buy” rating and $20 price target. The stock closed at $16.10 on July 24.Read More
BioLight Life Sciences (TASE:BOLT) announced successful results from its glaucoma insert, VS101, (Eye-D latanoprost) in a Phase 1/2a clinical trial, which demonstrated its ability to lower intraocular pressure (IOP) for a 12-week period, with a favorable safety profile.Read More
Microbix Biosystems (TSX:MBX) has appointed Cameron Groome as its president and CEO, with Vaughn Embro-Pantalony retiring from those positions but remaining an executive director, working closely with Mr. Groome to ensure a smooth leadership transition.Read More
H.C. Wainwright initiated coverage of Catabasis Pharmaceuticals (NASDAQ:CATB) with a “buy” rating and $14 price target. The stock closed at $3.59 on Dec. 21.Read More
Analysts at Stifel and BTIG initiated coverage of Obalon Therapeutics (NASDAQ:OBLN) with “buy” ratings and price targets of $18 and $20, respectively. The stock closed at $13.80 on Friday.
“Obalon appears poised for dramatic top-line growth with its highly-differentiated intragastric balloon system, already FDA-approved to treat 30-to-40 body mass index range obese patients,” writes Rick Wise of Stifel.Read More
Stereotaxis (NASDAQ:STXS) has signed definitive agreements for multiple transactions that significantly strengthen its financial position and help accelerate and enhance its strategic market growth initiatives.
The transactions include an equity financing of $24-million, satisfaction in full of outstanding debt to Healthcare Royalty Partners for a payment of $13-million, and the addition to the board of three new directors with significant operational and financial experience in the medical device industry.Read More
Closely-held AmorChem has spun out Mperia Therapeutics, a start-up company focusing on a novel immunotherapy approach based on CD36 cell receptor drug-ligands.
All rights to the CD36 technology initially held by AmorChem have been transferred to Mperia, with a first Series A investment of $1-million. The capital injection will allow Mperia to pursue early-stage development of lead candidates for the treatment of dry age-related macular degeneration (AMD), a leading cause of blindness in seniors.Read More
H.C. Wainwright initiated coverage of Mirna Therapeutics (NASDAQ:MIRN) with a ‘buy” rating and $6 price target, saying the company’s promising microRNA technology “could be a gift to long-term investors.” The stock was quoted at $2.50 on Monday afternoon.
“We believe the current Mirna share price offers an attractive entry point for long-term investors, as the stock is trading well below the $73-million June cash position,” writes analyst Shaunak Deepak.Read More
Analysts at BTIG Research, Piper Jaffray and William Blair initiated coverage of Tactile Systems Technology (NASDAQ:TCMD) with “buy,” “overweight” and “outperform” ratings, respectively.
Tactile makes pneumatic compression devices (PCD) to treat lymphedema, along with a chronic venous leg ulcer product. Tactile closed an IPO of 4,120,000 shares at $10 apiece earlier this month. The stock was changing hands at $12.98 at mid-day Monday.Read More
Roth Capital Partners lowered its price target for “buy-rated” GenVec (NASDAQ:GNVC) to $2 from $8, even though the FDA lifted the clinical hold on CGF166, being run worldwide by partner Novartis. The stock closed at 60 cents on Friday.
“This is an important milestone for the GenVec as CGF166 could be the first gene therapy approved for hearing loss,” writes analyst Joseph Pantginis. New patients will be entering cohort 4 in the dose escalation phase and the study is still expected to be complete in 2017.Read More
Roth Capital Partners has resumed coverage of Fibrocell Science (NASDAQ:FCSC) with a “buy” rating and $7 price target. The stock closed at $2.12 on Monday.
Fibrocell leverages its expertise with fibroblasts to target diseases of the skin, connective tissue and joints. The technology can take advantage of the inherent properties of fibroblasts, but also brings to bear the power of gene therapy, which can treat monogenic diseases, including those with significant unmet medical needs.Read More
BioLight Life Sciences (TASE:BOLT) has obtained worldwide rights, excluding Israel and Italy, for the manufacturing, distribution, sales and marketing of a groundbreaking new eye drop product for the treatment of dry eye syndrome (DES) and other ophthalmic indications.
The product was in-licensed from Fischer Pharmaceuticals and RAMOT, the technology transfer arm of the Tel Aviv University.Read More